
In the spring, we will participate in the 1st Czechoslovak Congress of Medical Genetics, which will take place from April 2–4, 2025, at the Cultural and Congress Center Elektra in the spa town of Luha...
Read moreVisit us at the 19th edition of the RANK 2025 conference, which will take place on March 19th and 20th at the Zlatá Štika Hotel in Pardubice. The conference is organized by the Czech Society of Clinic...
Read moreWe would like to invite you to the 23rd Kapras Day on the topic of "Clinical Genetics," which will take place on Wednesday, February 26, 2025, in the Congress Hall of Hotel Olšanka in Prague. We loo...
Read moreThe AmoyDx BCR-ABL Mutation Detection Kit is a sensitive and selective assay for the detection of the T315I mutation in the BCR-ABL gene. The majority (95%) of patients with chronic myelogenous leukemia (CML) have a chromosomal rearrangement that produces the BCR-ABL1 fusion oncogene. Patients with CML typically respond very well to treatment with the tyrosine kinase inhibitor imatinib mesylate [1], known as Gleevec in the US and Glivec in Europe. However, CML cells in patients treated with TKIs may develop resistance to the drug due to the appearance of the T315I point mutation in the BCR-ABL kinase domain [2]. New inhibitors such as dasatinib and nilotinib are significantly more potent than imatinib and may overcome resistance.